Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02632110 · ClinicalTrials.gov registry record · Phase 2
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
A Phase 2 study, sponsored by DUSA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT02632110: Completed Phase 2 study, sponsored by DUSA Pharmaceuticals.
NCT02632110 is a Phase 2 study that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 137 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02632110, a Phase 2 study, has completed, sponsored by DUSA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the viability of microneedle lesion preparation (MN) to enhance treatment benefit when performed prior to ALA PDT to an actinic keratosis (AK) field on the face.
Primary Outcome
Number of AK Fields with 0 lesions
Interventions
- DRUG ALA
- DRUG Topical Solution Vehicle
- DEVICE IBL 10 mW
- PROCEDURE Microneedle lesion preparation
- DEVICE IBL 20 mW
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2016-03 |
| Est. Completion | 2016-09-12 |
| Phase | Phase 2 |
What the finished NCT02632110 record still lists
NCT02632110 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which ALA is the first listed.
NCT02632110 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02632110 about?
NCT02632110 is a clinical study titled "Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face". The purpose of this study is to determine the viability of microneedle lesion preparation (MN) to enhance treatment benefit when performed prior to ALA PDT to an actinic keratosis (AK) field on the face.
What is the current status of trial NCT02632110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2016-03. Estimated completion is 2016-09-12.
What interventions are being tested in trial NCT02632110?
The interventions under investigation include: ALA (DRUG), Topical Solution Vehicle (DRUG), IBL 10 mW (DEVICE), Microneedle lesion preparation (PROCEDURE), IBL 20 mW (DEVICE).
Who is sponsoring clinical trial NCT02632110?
This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02632110's enrollment target sits among peer trials
137 527th of 2000 higher than 1,474 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia